Clinical trials: SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
COVID, Sars-CoV2
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease
- Conditions
- COVID, Sars-CoV2, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress
- Trial name
- NCT04419025
- Testing
- N-acetylcysteine
- Where
- 4 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Cambridge Health Alliance
Covid19, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
Efficacy of Nicotine in Preventing COVID-19 Infection
The coronavirus disease (COVID-19) epidemic represents a major therapeutic challenge. The highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) and the long duration of the disease have led to a massive…
- Trial name
- NICOVID-PREV (NCT04583410)
- Testing
- Nicotine patch
- Where
- 4 sites in France
- Volunteers
- 1,633 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID, Covid-19
A Study of ResCure™ to Treat COVID-19 Infection
This is a Phase I open-label interventional study which will test the efficacy of ResCure™ in the treatment of patients with COVID-19 infection.
- Conditions
- COVID, Covid-19, Corona Virus Infection, Sars-CoV2
- Trial name
- NCT04395716
- Testing
- ResCure™
- Where
- United States
- Sponsor
- ProgenaBiome
Covid19, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients
There is currently no known treatment for COVID19. Active smokers are infrequent among patients with COVID-19 which has led our team to hypothesize that nicotine is responsible for this protective effect via the nicotinic…
- Trial name
- NICOVID-REA (NCT04598594)
- Testing
- Patch, Nicotine
- Where
- 18 sites in France
- Volunteers
- 220 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Covid19, COVID-19 Pneumonia
NAC for Attenuation of COVID-19 Symptomatology
The objective of this study is to determine whether oral NAC is effective at attenuating COVID-19 disease symptom severity and duration of symptoms.
- Conditions
- Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Lower Respiratory Infection
- Trial name
- NACinCOVID2 (NCT05074121)
- Testing
- N-acetylcysteine
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Cambridge Health Alliance
Coronavirus, Respiratory Failure
Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial
Background: A novel Coronavirus (SARS-CoV-2) described in late 2019 in Wuhan, China, has led to a pandemic and to a specific coronavirus-related disease (COVID-19), which is mainly characterized by a respiratory involvement.
- Conditions
- Coronavirus, Respiratory Failure, Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere, SARS-CoV-2
- Trial name
- ATCO (NCT04332666)
- Testing
- Angiotensin 1-7
- Volunteers
- 60 people
- Sponsor
- Erasme University Hospital
COVID, COVID-19
A Study of Combination Therapies to Treat COVID-19 Infection
This study seeks to determine whether dual or quadruple therapy is more effective in treating COVID-19.
- Conditions
- COVID, COVID-19, Corona Virus Infection, Coronavirus Infection
- Trial name
- NCT04459702
- Testing
- hydroxychloroquine, Azithromycin, Ritonavir
- Where
- United States
- Sponsor
- ProgenaBiome
Coronavirus, Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere
COVID-19 Risk Stratification
The investigators seek to derive and validate a clinically useful risk score for patients with Coronavirus Disease 2019 to aide clinicians in the safe discharge of patients.
- Trial name
- NCT04339387
- Where
- United States
- Volunteers
- 1,326 people
- Sponsor
- Brigham and Women's Hospital
SARS-CoV 2, SARS Pneumonia
Cardiovascular Implications of COVID-19
At the end of December of 2019, a series of patients in Wuhan, China were struck with a mysterious respiratory infection. These isolated events have rapidly grown into a deadly, global pandemic.
- Conditions
- SARS-CoV 2, SARS Pneumonia, COVID-19, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
- Trial name
- NCT04435457
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Texas Southwestern Medical Center
Coronavirus, Coronavirus Infection
Observational Study of COVID-19 Treatment Efficacy
To compare various treatments provided to positive COVID-19 patients at locations across the OSF Ministry. Provide the opportunity to compare the effectiveness of various treatments and treatment timelines provided to specific…
- Conditions
- Coronavirus, Coronavirus Infection, Corona Virus Infection, COVID
- Trial name
- NCT04369989
- Testing
- No intervention
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- OSF Healthcare System
Covid19, SARS (Severe Acute Respiratory Syndrome)
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
The study is a double-blind, randomized, placebo-controlled, multi-center, Phase 3 study to evaluate the efficacy and safety of fostamatinib in COVID-19 subjects.
- Conditions
- Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
- Trial name
- NCT04629703
- Testing
- Fostamatinib
- Where
- 47 sites in United States, Argentina and 2 more
- Volunteers
- 280 people
- Sponsor
- Rigel Pharmaceuticals